Icu Medical Stock Fair Value – Public Sector Pension Fund Boosts Stake in ICU Medical by 8.4% in Q2
September 27, 2024
☀️Trending News
ICU ($NASDAQ:ICUI) Medical, Inc. is a leading medical device company that specializes in providing innovative, safe, and effective products for the critical care and hospital markets. Their products are used in various medical procedures such as infusion therapy, oncology, and critical care applications. Recently, the company’s stock caught the attention of the Public Sector Pension Investment Board, one of the largest pension funds in Canada. In the second quarter of this year, the pension fund increased its stake in ICU Medical by 8.4%, making it one of the top institutional shareholders of the company. This move by the Public Sector Pension Investment Board indicates a strong vote of confidence in ICU Medical’s performance and potential for future growth. It also highlights the attractiveness of the company’s stock to institutional investors. This could potentially benefit the company in terms of strategic guidance and access to new opportunities.
The rise in the pension fund’s stake also reflects the company’s strong financial performance in recent years. This was driven by increased demand for their products due to the ongoing global pandemic. With a solid financial standing and a strong backing from institutional investors like the Public Sector Pension Investment Board, ICU Medical is well-positioned to continue its growth trajectory. The company has a track record of delivering value to its shareholders, and this latest development only adds to its appeal for potential investors. In conclusion, the increase in stake by the Public Sector Pension Investment Board is a testament to ICU Medical’s strong market position, innovative products, and promising future outlook. It is a noteworthy development for both the company and its shareholders, and it will be interesting to see how this partnership further strengthens ICU Medical’s standing in the medical device industry.
Analysis – Icu Medical Stock Fair Value
After conducting a thorough analysis of ICU MEDICAL‘s financials, I can confidently say that the company currently presents a strong investment opportunity. The company’s financials displayed below showcase its stability and potential for growth. One of the key factors that we at GoodWhale consider when evaluating a stock is its intrinsic value. Our proprietary Valuation Line has calculated the intrinsic value of ICU MEDICAL’s share to be approximately $217.1. This indicates that the stock is currently undervalued by around 19.5%, making it an attractive investment prospect. It is worth noting that the current market price of ICU MEDICAL’s stock is $174.73, which indicates that it is trading at a fair price. However, our analysis suggests that it is undervalued and has room for growth. This makes it a good opportunity for investors looking to enter the market or add to their portfolio. Overall, our analysis of ICU MEDICAL’s financials and valuation shows that it is a solid investment option. With its current undervaluation and potential for growth, investors can expect a favorable return on their investment. As always, we advise investors to conduct their own research and consult with a financial advisor before making any investment decisions. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icu Medical. More…
| Total Revenues | Net Income | Net Margin |
| 2.26k | -29.66 | -0.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icu Medical. More…
| Operations | Investing | Financing |
| 166.2 | -87.95 | -35.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icu Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.38k | 2.26k | 87.96 |
Key Ratios Snapshot
Some of the financial key ratios for Icu Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.1% | -29.3% | 1.1% |
| FCF Margin | ROE | ROA |
| 3.2% | 0.7% | 0.3% |
Peers
It operates in a highly competitive market that includes major competitors such as Ypsomed Holding AG, Coloplast A/S, and Cardiovascular Systems Inc. These companies all strive to provide the best quality products and services to meet the needs of their customers.
– Ypsomed Holding AG ($LTS:0QLQ)
Ypsomed Holding AG is a leading Swiss medical technology company that designs, develops, and manufactures healthcare products for delivery of drugs and other treatments. The company has a market capitalization of 2.34 billion as of 2022, reflecting the confidence of investors in the company’s potential and its ability to grow in the coming years. Ypsomed Holding AG also has a Return on Equity of 4.93%, which is a measure of the company’s profitability relative to its shareholders’ equity. This indicates that the company is using its resources efficiently and delivering value to its shareholders.
– Coloplast A/S ($LTS:0QBO)
Coloplast A/S is a Danish medical device company that develops, manufactures, and markets medical products and services worldwide. The company has a market cap of 183.14B as of 2022 and a Return on Equity (ROE) of 50.58%. The market cap is an indication of the overall size of the company and its potential to generate profits. A high ROE indicates that the company is able to generate a significant return on the invested capital, making it an attractive investment. Coloplast is known for its products and services in the areas of urology, continence care, ostomy care, and wound and skin care, which have helped to ensure the company’s continued success.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Cardiovascular Systems Inc is a medical device company that develops, manufactures, and markets innovative interventional treatment systems for peripheral and coronary artery disease. The company has a market cap of 576.3M as of 2022 and a Return on Equity of -9.45%. This indicates that the company is not generating enough profits to cover its costs, which is not a good sign for the investors. Despite this, the company continues to innovate and develop new products in order to improve its financial performance.
Summary
Public Sector Pension Investment Board increased its stake in ICU Medical, Inc. by 8.4% during the second quarter. This indicates confidence in the company’s financial performance and growth potential. The increase in investment could potentially lead to higher returns for the pension board.
This move also suggests that ICU Medical is a well-managed and stable company that is worth investing in. The board’s decision to increase their position may also influence other investors to consider adding ICU Medical to their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
